Advances in the synthesis and anticancer activities of pyrimidine based scaffolds

This review explores the synthesis, structural diversity, and anticancer potential of various pyrimidine based compounds and its molecular hybrids, underscoring their promise in oncology. The compounds discussed include pyrimidine-based derivatives, pyrazolo[1,5-a]pyrimidines, pyrano[2,3-d]pyrimidine conjugates, and isoxazole-linked scaffolds, evaluated against cancer cell lines such as MCF-7, A549, SiHa, and Colo-205. Many compounds demonstrated significant cytotoxicity, with IC₅₀ values markedly lower than standard chemotherapeutic agents like doxorubicin and 5-fluorouracil. The integration of functional groups, including sulfonyl moieties, pyrrolidine rings, and spiro-linked frameworks, was critical in enhancing anticancer activity. Notably, certain pyrimidinic selenourea conjugates exhibited superior potency, while spiro[benzo[4,5]thieno[2,3-d]pyrimidine] derivatives achieved nanomolar IC₅₀ values. Several compounds also displayed selective cytotoxicity towards cancer cells while sparing normal cells, indicating potential for reduced off-target effects. Despite promising in vitro results, limited mechanistic insights remain a challenge, warranting detailed investigations into their actions on cellular pathways such as apoptosis and angiogenesis. Future directions include refining lead structures to improve pharmacokinetic profiles and employing computational methods like molecular docking and QSAR for target prediction and optimization. Additionally, exploring combination therapies with established drugs and developing sustainable synthetic protocols aligned with green chemistry principles will enhance clinical translation potential. Overall, these findings highlight the potential of novel heterocyclic frameworks as next-generation anticancer agents, emphasizing the need for comprehensive preclinical studies to advance them towards clinical application in addressing the global cancer burden.